GlobeNewsWire
24 Jun 2026, 01:13 UTC · 2h ago
uniQure Announces Pricing of Upsized $225 Million Public Offering
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
24 Jun 2026, 01:13 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
uniQure is pricing a public offering of 4,945,055 ordinary shares at $45.50 per share. — Public offerings typically cause short-term share price dilution for existing shareholders.
-0.40The company expects to raise approximately $225 million in aggregate gross proceeds from the offering. — Increased liquidity strengthens the balance sheet to fund the development of its gene therapy pipeline.
+0.30Underwriters have a 30-day option to purchase up to 741,758 additional ordinary shares. — Potential for further dilution if the over-allotment option is exercised.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is successfully raising approximately $225 million in gross proceeds through a public offering to fund its gene therapy pipeline.
Royal Bank of Canada is acting as a joint bookrunning manager for the offering, generating fee income.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
12h ago
